Please try another search
Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems. It uses its platform for developing a portfolio of programs for treating cancer, autoimmune, hematologic disorders, prioritizing sickle cell, beta-thalassemia, and hemophilia A diseases, as well as for other tissues and cell types, including retina, skeletal muscle, and central nervous system. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
Jason P. Rhodes | 51 | 2017 | Independent Chairman |
Charles A. Rowland | 63 | 2018 | Independent Director |
Andrew M. Scharenberg | - | - | Chairman of Scientific Advisory Board |
Cameron Geoffrey McDonough | 53 | 2017 | President, CEO & Director |
Adrian Thrasher | - | - | Member of Scientific Advisory Board |
Jeffrey M. Jonas | 70 | 2018 | Independent Director |
Kevin Joseph Fitzgerald | 54 | - | Member of Scientific Advisory Board |
Katherine Fitzgerald | - | 2019 | Member of Scientific Advisory Board |
Ronald H. W. Cooper | 60 | 2021 | Independent Director |
Richard Thompson | - | 2018 | Member of Scientific Advisory Board |
Donald William Nicholson | 65 | 2017 | Independent Director |
Catherine Stehman-Breen | 60 | 2017 | Independent Director |
Anthony G. Quinn | 61 | 2017 | Independent Director |
Gustav A. Christensen | 75 | 2017 | Independent Director |
Steven F. Dowdy | - | 2019 | Member of Scientific Advisory Board |
Dannielle Appelhans | 40 | 2022 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review